Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc has recently enhanced its financial stability through successful equity financings and option exercises, resulting in a significant increase in financing income to $284K for the quarter and $611K year-to-date. The company is poised for substantial growth with the impending launches of its LIBERTY Endovascular Robotic System in the US and EU, backed by a strengthened commercial infrastructure and positive provider feedback, which underscores the product's market potential. Furthermore, strategic partnerships with experienced logistics providers are set to streamline operations, indicating a robust foundation for future revenue acceleration as Microbot enters new markets.

Bears say

Microbot Medical faces significant risks that contribute to a negative outlook on its stock, including potential delays in commercializing its LIBERTY Endovascular Robotic System and challenges in expanding its application to cardio and neuro cases. The company is also confronted with reimbursement issues and a lack of near-term profitability, which may erode its financial stability. Additionally, the absence of robust data from randomized controlled trials and possible setbacks in obtaining international regulatory approvals further heighten the uncertainty surrounding its market adoption and sales potential.

Microbot Medical (MBOT) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.